Does the media refer more to AXSM or JAZZ?

In the previous week, Axsome Therapeutics had 1 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 13 mentions for Axsome Therapeutics and 12 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.65 beat Jazz Pharmaceuticals' score of 0.44 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AXSM or TEVA?

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Axsome Therapeutics. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Teva Pharmaceutical Industries' score of 0.48 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 9 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor AXSM or ONC?

In the previous week, Axsome Therapeutics had 11 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for Axsome Therapeutics and 2 mentions for BeOne Medicines. Axsome Therapeutics' average media sentiment score of 0.65 beat BeOne Medicines' score of 0.56 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RPRX or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 13 mentions for Axsome Therapeutics and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.65 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AXSM or ZTS?

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $638.50M 17.05 -$183.17M -$3.75 N/A Zoetis $9.47B 3.12 $2.67B $6.07 11.78

Is AXSM or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -24.68%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -24.68% -265.55% -28.10% Zoetis 27.49% 74.89% 18.59%

Does the media favor AXSM or ZTS?

In the previous week, Zoetis had 1 more articles in the media than Axsome Therapeutics. MarketBeat recorded 14 mentions for Zoetis and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Zoetis' score of 0.52 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

Axsome Therapeutics (AXSM) Competitors

$207.78 -6.50 (-3.03%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$207.16 -0.62 (-0.30%)

As of 09/18/2026 07:46 PM Eastern

Compare

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

Should you buy Axsome Therapeutics stock or one of its competitors? Axsome Therapeutics's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Axsome Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A
Jazz Pharmaceuticals	$4.27B	3.66	-$356.15M	$14.50	16.60

In the previous week, Axsome Therapeutics had 1 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 13 mentions for Axsome Therapeutics and 12 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.65 beat Jazz Pharmaceuticals' score of 0.44 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -24.68%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Axsome Therapeutics currently has a consensus target price of $267.60, suggesting a potential upside of 28.79%. Jazz Pharmaceuticals has a consensus target price of $286.72, suggesting a potential upside of 19.10%. Given Axsome Therapeutics' higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Axsome Therapeutics (NASDAQ:AXSM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Axsome Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Axsome Therapeutics' net margin of -24.68%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Axsome Therapeutics. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Teva Pharmaceutical Industries' score of 0.48 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	9 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A
Teva Pharmaceutical Industries	$17.26B	2.64	$1.41B	$0.60	65.18

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Axsome Therapeutics currently has a consensus target price of $267.60, indicating a potential upside of 28.79%. Teva Pharmaceutical Industries has a consensus target price of $43.10, indicating a potential upside of 10.21%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Summary

Teva Pharmaceutical Industries beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

Axsome Therapeutics (NASDAQ:AXSM) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Axsome Therapeutics presently has a consensus price target of $267.60, suggesting a potential upside of 28.79%. BeOne Medicines has a consensus price target of $402.71, suggesting a potential upside of 14.79%. Given Axsome Therapeutics' higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeOne Medicines has a net margin of 10.70% compared to Axsome Therapeutics' net margin of -24.68%. BeOne Medicines' return on equity of 14.23% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
BeOne Medicines	10.70%	14.23%	7.82%

In the previous week, Axsome Therapeutics had 11 more articles in the media than BeOne Medicines. MarketBeat recorded 13 mentions for Axsome Therapeutics and 2 mentions for BeOne Medicines. Axsome Therapeutics' average media sentiment score of 0.65 beat BeOne Medicines' score of 0.56 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A
BeOne Medicines	$5.34B	7.21	$286.93M	$5.68	61.77

Axsome Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Summary

BeOne Medicines beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Royalty Pharma has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to Axsome Therapeutics' net margin of -24.68%. Royalty Pharma's return on equity of 30.01% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

In the previous week, Axsome Therapeutics had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 13 mentions for Axsome Therapeutics and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.65 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.12	$770.95M	$1.45	40.28
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A

Royalty Pharma currently has a consensus price target of $61.29, indicating a potential upside of 4.92%. Axsome Therapeutics has a consensus price target of $267.60, indicating a potential upside of 28.79%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Royalty Pharma beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Zoetis?

Axsome Therapeutics (NASDAQ:AXSM) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -24.68%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Zoetis	27.49%	74.89%	18.59%

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A
Zoetis	$9.47B	3.12	$2.67B	$6.07	11.78

Axsome Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $267.60, suggesting a potential upside of 28.79%. Zoetis has a consensus target price of $101.08, suggesting a potential upside of 41.30%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Zoetis had 1 more articles in the media than Axsome Therapeutics. MarketBeat recorded 14 mentions for Zoetis and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Zoetis' score of 0.52 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Zoetis beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.22B	$12.48B	$7.26B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-55.41	797.25	275.79	25.40
Price / Sales	17.05	950.97	695.58	114.44
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	118.73	10.53	10.46	6.33
Net Income	-$183.17M	$2.82B	$3.49B	$358.33M
7 Day Performance	-5.88%	1.69%	0.59%	1.12%
1 Month Performance	-4.78%	0.83%	-2.01%	-2.67%
1 Year Performance	79.20%	3.90%	18.09%	6.01%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	3.804 of 5 stars	$207.78 -3.0%	$267.60 +28.8%	+75.1%	$11.22B	$638.50M	N/A	925	Analyst Forecast
JAZZ Jazz Pharmaceuticals	4.3551 of 5 stars	$245.87 +0.0%	$286.72 +16.6%	+83.5%	$15.96B	$4.27B	16.96	2,890
TEVA Teva Pharmaceutical Industries	3.5091 of 5 stars	$38.34 +3.4%	$43.10 +12.4%	+112.1%	$43.22B	$17.26B	63.89	33,950	Trending News
ONC BeOne Medicines	3.4973 of 5 stars	$353.83 +2.1%	$402.71 +13.8%	+2.3%	$38.04B	$5.34B	62.29	12,000
RPRX Royalty Pharma	3.7999 of 5 stars	$59.05 +0.8%	$61.29 +3.8%	+63.5%	$33.70B	$2.38B	40.72	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Summary

How does Axsome Therapeutics compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Which has more volatility & risk, AXSM or JAZZ?

Which has better earnings and valuation, AXSM or JAZZ?

Does the media refer more to AXSM or JAZZ?

Do insiders & institutionals hold more shares of AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Do analysts rate AXSM or JAZZ?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Which has more volatility and risk, AXSM or TEVA?

Is AXSM or TEVA more profitable?

Does the media refer more to AXSM or TEVA?

Which has preferable earnings & valuation, AXSM or TEVA?

Do institutionals and insiders have more ownership in AXSM or TEVA?

Do analysts prefer AXSM or TEVA?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Do analysts rate AXSM or ONC?

Do institutionals and insiders hold more shares of AXSM or ONC?

Is AXSM or ONC more profitable?

Does the media favor AXSM or ONC?

Which has stronger earnings & valuation, AXSM or ONC?

Which has more volatility and risk, AXSM or ONC?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Do insiders & institutionals hold more shares of RPRX or AXSM?

Which has more volatility & risk, RPRX or AXSM?

Is RPRX or AXSM more profitable?

Does the media prefer RPRX or AXSM?

Which has stronger valuation and earnings, RPRX or AXSM?

Do analysts rate RPRX or AXSM?

Summary

How does Axsome Therapeutics compare to Zoetis?

Is AXSM or ZTS more profitable?

Which has higher valuation & earnings, AXSM or ZTS?

Which has more volatility & risk, AXSM or ZTS?

Do analysts prefer AXSM or ZTS?

Do insiders and institutionals have more ownership in AXSM or ZTS?

Does the media favor AXSM or ZTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools